WO2004080418A3 - Nucleic acid compounds for inhibiting angiogenesis and tumor growth - Google Patents

Nucleic acid compounds for inhibiting angiogenesis and tumor growth Download PDF

Info

Publication number
WO2004080418A3
WO2004080418A3 PCT/US2004/007491 US2004007491W WO2004080418A3 WO 2004080418 A3 WO2004080418 A3 WO 2004080418A3 US 2004007491 W US2004007491 W US 2004007491W WO 2004080418 A3 WO2004080418 A3 WO 2004080418A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
acid compounds
tumor growth
inhibiting angiogenesis
compositions
Prior art date
Application number
PCT/US2004/007491
Other languages
French (fr)
Other versions
WO2004080418A2 (en
Inventor
Ramachandra Reddy
Parkash Gill
Original Assignee
Vasgene Therapeutics Inc
Ramachandra Reddy
Parkash Gill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasgene Therapeutics Inc, Ramachandra Reddy, Parkash Gill filed Critical Vasgene Therapeutics Inc
Priority to JP2006507095A priority Critical patent/JP4762889B2/en
Priority to CA002518898A priority patent/CA2518898A1/en
Priority to EP04720327A priority patent/EP1606305A4/en
Priority to AU2004220525A priority patent/AU2004220525B2/en
Publication of WO2004080418A2 publication Critical patent/WO2004080418A2/en
Publication of WO2004080418A3 publication Critical patent/WO2004080418A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Abstract

In certain embodiments, this present disclosure provides nucleic acid compounds, compositions, and methods for inhibiting Ephrin B2 or EphB4 expression. In certain embodiments, the present disclosure provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.
PCT/US2004/007491 2003-03-12 2004-03-12 Nucleic acid compounds for inhibiting angiogenesis and tumor growth WO2004080418A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2006507095A JP4762889B2 (en) 2003-03-12 2004-03-12 Nucleic acid compounds for inhibiting angiogenesis and tumor growth
CA002518898A CA2518898A1 (en) 2003-03-12 2004-03-12 Nucleic acid compounds for inhibiting angiogenesis and tumor growth
EP04720327A EP1606305A4 (en) 2003-03-12 2004-03-12 Nucleic acid compounds for inhibiting angiogenesis and tumor growth
AU2004220525A AU2004220525B2 (en) 2003-03-12 2004-03-12 Nucleic acid compounds for inhibiting angiogenesis and tumor growth

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45443203P 2003-03-12 2003-03-12
US45430003P 2003-03-12 2003-03-12
US60/454,300 2003-03-12
US60/454,432 2003-03-12

Publications (2)

Publication Number Publication Date
WO2004080418A2 WO2004080418A2 (en) 2004-09-23
WO2004080418A3 true WO2004080418A3 (en) 2005-05-06

Family

ID=32994555

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2004/007755 WO2004080425A2 (en) 2003-03-12 2004-03-12 Polypeptide compounds for inhibiting angiogenesis and tumor growth
PCT/US2004/007491 WO2004080418A2 (en) 2003-03-12 2004-03-12 Nucleic acid compounds for inhibiting angiogenesis and tumor growth

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2004/007755 WO2004080425A2 (en) 2003-03-12 2004-03-12 Polypeptide compounds for inhibiting angiogenesis and tumor growth

Country Status (6)

Country Link
US (5) US7585967B2 (en)
EP (2) EP1605961A4 (en)
JP (3) JP4762889B2 (en)
AU (3) AU2004220525B2 (en)
CA (2) CA2518898A1 (en)
WO (2) WO2004080425A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
AU2002951409A0 (en) * 2002-09-16 2002-09-26 North Western Adelaide Health Services Methods for regulating cancer
WO2004028551A1 (en) 2002-09-24 2004-04-08 The Burnham Institute Novel agents that modulate eph receptor activity
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
AU2004220525B2 (en) 2003-03-12 2011-03-31 Vasgene Therapeutics, Inc. Nucleic acid compounds for inhibiting angiogenesis and tumor growth
CN102746401A (en) 2004-03-12 2012-10-24 瓦斯基因治疗公司 Polypeptide compound for inhibiting angiogenesis and tumor growth
CN101072797B (en) * 2004-03-12 2012-05-09 瓦斯基因治疗公司 Antibody binding EPHB4, inhibiting angiogenesis and tumor growth
JP2007320850A (en) * 2004-08-24 2007-12-13 Kyowa Hakko Kogyo Co Ltd Anti-ephrin b2 antibody
EP1799867A2 (en) * 2004-09-23 2007-06-27 Vasgene Therapeutics, Inc. Compositions and methods for detecting and treating tumors
EP2301963A1 (en) 2004-09-23 2011-03-30 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
DE102004054016A1 (en) * 2004-11-09 2006-05-11 Robert Bosch Gmbh Control unit for controlling and / or regulating at least one vehicle function
EP1814899A4 (en) * 2004-11-18 2008-09-03 Univ Illinois Multicistronic sirna constructs to inhibit tumors
JP5007238B2 (en) * 2005-01-06 2012-08-22 ジェネンテック， インコーポレイテッド Methods and compositions useful for cancer prognosis, diagnosis and treatment
KR20070118230A (en) * 2005-01-27 2007-12-14 더 번햄 인스티튜트 Ephb receptor-binding peptides
FR2889200B1 (en) 2005-07-27 2008-01-04 Inst Vaisseaux Et Du Sang Ass CELLULAR / LIGAND MARKER SYSTEM, WHERE THE MARKER IS OF THE EPH TYPE, CELLULAR MATERIAL COMPRISING SAID SYSTEM, PROCESS FOR THE PREPARATION AND PROANGIOGENIC USE
CA2623387A1 (en) * 2005-09-23 2007-04-05 Vasgene Therapeutics, Inc. Use of ephrinb2 directed agents for the treatment or prevention of viral infections
AR059096A1 (en) 2006-01-20 2008-03-12 Genentech Inc ANTI-EFRINE ANTIBODIES -B2 AND METHODS USING THESE
AU2007283022B2 (en) 2006-08-08 2011-07-28 Rheinische Friedrich-Wilhelms-Universitat Bonn Structure and use of 5' phosphate oligonucleotides
WO2009006336A1 (en) * 2007-06-28 2009-01-08 Sylgen Laboratories, Inc. Compositions and methods for inhibiting angiogenesis and tumorigenesis
BRPI0815399A2 (en) 2007-08-13 2019-09-24 Vasgene Therapeutics Inc cancer treatment using humanized antibodies that bind ephb4
US8357501B2 (en) 2007-11-29 2013-01-22 Molecular Health Gmbh Tissue protective erythropoietin receptor (NEPOR) and methods of use
PL2492355T3 (en) * 2007-11-29 2015-09-30 Molecular Health Gmbh Tissue protective erythropoietin receptor (nepor) and methods of use
WO2009141146A1 (en) 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
US20120207743A1 (en) * 2011-02-14 2012-08-16 Allergan, Inc. Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
JP2015071566A (en) * 2013-10-03 2015-04-16 住友ベークライト株式会社 Pharmaceutical composition of fgf4 gene amplification tumor
JP7057975B2 (en) * 2016-12-14 2022-04-21 国立大学法人信州大学 Chimeric antigen receptor gene-modified lymphocytes with cell-killing effect
EP3908313A4 (en) * 2019-01-10 2022-10-05 Massachusetts Institute of Technology Functional analysis of cancer cells
EP4105328A1 (en) 2021-06-15 2022-12-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Antisense-oligonucleotides for prevention of kidney dysfunction promoted by endothelial dysfunction by ephrin-b2 suppression
WO2023224096A1 (en) * 2022-05-18 2023-11-23 国立研究開発法人国立がん研究センター Cancer vaccine using common cancer antigen cocktail, tcr/car-t cell therapeutic, companion diagnostic method, and method for diagnosing cancer onset risk by blood-circulating cancer cell detection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110150A1 (en) * 2002-12-10 2004-06-10 Isis Pharmaceuticals Inc. Modulation of Ephrin-B2 expression
US20040234520A1 (en) * 1998-11-20 2004-11-25 Michel Aguet Uses for Eph receptor antagonists and agonists
US20040247592A1 (en) * 2001-07-03 2004-12-09 Roifman Chaim M. Ephrin and eph receptor mediated immune modulation

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH04218000A (en) 1990-02-13 1992-08-07 Kirin Amgen Inc Modified polypeptide
AU655299B2 (en) 1991-06-21 1994-12-15 Ludwig Institute For Cancer Research Ltd A novel receptor-type tyrosine kinase and use thereof
EP0624192A1 (en) 1992-01-22 1994-11-17 New England Deaconess Hospital Novel protein tyrosine kinases
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US6331302B1 (en) 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
WO2002081494A1 (en) * 2001-03-26 2002-10-17 Sirna Therapeutics, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
HU225646B1 (en) 1992-10-28 2007-05-29 Genentech Inc Hvegf receptors as vascular endothelial cell growth factor antagonists
WO1994011020A1 (en) 1992-11-13 1994-05-26 Amgen Inc. Eck receptor ligands
US5824303A (en) 1992-11-13 1998-10-20 Amgen Inc. Eck receptor ligands
US5512591A (en) 1993-02-18 1996-04-30 President And Fellows Of Harvard College Treatments for diseases characterized by neovascularization
ES2152753B1 (en) 1993-03-29 2001-09-01 Ct Investig Energeticas Ciemat TRANSGENIC ANIMALS FOR THE DETERMINATION OF AGENTS THAT STIMULATE OR REPRESSE EPIDERMIC HYPERPROLIFERATION AND HAIR GROWTH
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5624899A (en) 1994-07-20 1997-04-29 Genentech Inc. Method for using Htk ligand
WO1996003043A1 (en) 1994-07-26 1996-02-08 Rutgers, The State University Of New Jersey Human brain specific kinase
US5795734A (en) 1994-09-19 1998-08-18 President And Fellows Of Harvard College EPH receptor ligands, and uses related thereto
EP0787148B1 (en) 1994-10-27 2004-04-07 Genentech, Inc. Al-1 neurotrophic factor, a ligand for an eph-related tyrosine kinase receptor
US6057124A (en) 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
WO1996026958A2 (en) 1995-02-27 1996-09-06 President And Fellows Of Harvard College Eph RECEPTOR LIGAND ELF-2
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
EP1382679A3 (en) 1995-09-08 2004-11-10 Genentech, Inc. Vascular Endothelial Growth Factor Related Protein (VRP) Antagonists
US6346398B1 (en) * 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US5837534A (en) 1995-11-14 1998-11-17 The Board Of Regents Of The University Of Texas System Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells
AUPN727795A0 (en) 1995-12-22 1996-01-18 Walter And Eliza Hall Institute Of Medical Research, The A novel receptor-type tyrosine kinase and use thereof
US6696557B1 (en) * 1996-04-19 2004-02-24 Genentech, Inc. AL-2 neurotrophic factor nucleic acid
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6413730B1 (en) 1996-07-05 2002-07-02 Mount Sinai Hospital Corporation Method for identifying compounds that inhibit or enhance activation of a transmembrane ligand for a receptor tyrosine kinase
UA73073C2 (en) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Substituted 3-cyan chinolines
WO1998045331A2 (en) 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
AU6887698A (en) 1997-04-08 1998-10-30 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
US6440954B1 (en) 1997-04-18 2002-08-27 President And Fellows Of Harvard College Inhibition of vascular smooth muscle cell proliferation
WO1999008696A1 (en) 1997-08-19 1999-02-25 Vanderbilt University METHODS FOR DETERMINING CELL RESPONSES THROUGH EphB RECEPTORS
AU9594598A (en) 1997-10-02 1999-04-27 Millennium Pharmaceuticals, Inc. Modulation of lerk-2-mediated cell adhesion
US6423685B1 (en) 1998-03-05 2002-07-23 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
CA2246664A1 (en) 1998-10-02 2000-04-02 Universite Paris 7 Vascular specific regulatory elements contained in the desmin 5' flanking region
AUPP674898A0 (en) 1998-10-27 1998-11-19 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment
US6150162A (en) * 1998-12-17 2000-11-21 Isis Pharmaceuticals Inc. Antisense modulation of CD44 expression
US6770633B1 (en) * 1999-10-26 2004-08-03 Immusol, Inc. Ribozyme therapy for the treatment of proliferative skin and eye diseases
AU2658701A (en) 2000-01-06 2001-07-16 Hospital For Sick Children, The Methods of modulation of the immune system
US20070026394A1 (en) * 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
WO2001072765A1 (en) * 2000-03-28 2001-10-04 Isis Pharmaceuticals, Inc. ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING
EP1274720A4 (en) * 2000-04-12 2004-08-18 Human Genome Sciences Inc Albumin fusion proteins
EP1274730A2 (en) 2000-04-21 2003-01-15 Amgen, Inc. Integrin/adhesion antagonists
US6271030B1 (en) * 2000-06-14 2001-08-07 Isis Pharmaceuticals, Inc. Antisense inhibition of C/EBP beta expression
US6277640B1 (en) * 2000-07-31 2001-08-21 Isis Pharmaceuticals, Inc. Antisense modulation of Her-3 expression
EP1392333A2 (en) 2000-08-03 2004-03-03 The University of Utah Research Foundation Manipulation of arterial-venous identity
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
WO2002026827A1 (en) 2000-09-29 2002-04-04 Novartis Ag Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules
US7136808B2 (en) * 2000-10-20 2006-11-14 Microsoft Corporation Detection and correction of errors in german grammatical case
CA2429460A1 (en) 2000-11-20 2002-05-23 California Institute Of Technology Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor
US20040259247A1 (en) * 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
AU2002243623A1 (en) 2001-01-26 2002-08-06 Regeneron Pharmaceuticals, Inc. Methods of imaging and targeting vasculature
WO2002061055A2 (en) 2001-01-31 2002-08-08 Mount Sinai Hospital Methods for regulating the kinase domain of ephb2
JP2004517638A (en) 2001-02-02 2004-06-17 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ Methods for identifying functional nucleic acids
WO2002079382A2 (en) 2001-03-30 2002-10-10 President And Fellows Of Harvard College B-ephrin regulation of g-protein coupled chemoattraction; compositions and methods of use
EP1390385A4 (en) * 2001-05-29 2004-11-24 Sirna Therapeutics Inc Nucleic acid based modulation of female reproductive diseases and conditions
WO2002102854A2 (en) 2001-06-20 2002-12-27 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
CA2633171C (en) 2001-06-20 2012-11-20 Genentech, Inc. Antibodies against tumor-associated antigenic target (tat) polypeptides
JP3876656B2 (en) * 2001-07-13 2007-02-07 住友金属工業株式会社 Threaded joints for pipes
AU2002353972A1 (en) * 2001-11-02 2003-05-19 Pfizer Products Inc. Lung cancer therapeutics and diagnostics
US20060241027A1 (en) 2002-02-07 2006-10-26 Hans-Peter Hauser Hiv inhibiting proteins
CA2485548A1 (en) 2002-05-10 2004-02-19 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
WO2003094859A2 (en) 2002-05-10 2003-11-20 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
WO2004020468A2 (en) 2002-08-28 2004-03-11 Maxygen Aps Interferon beta-like molecules for treatment of cancer
AU2003260169B9 (en) * 2002-09-16 2011-06-09 The Queen Elizabeth Hospital Research Foundation Inc. Methods for regulating cancer
AU2002951409A0 (en) 2002-09-16 2002-09-26 North Western Adelaide Health Services Methods for regulating cancer
ES2440284T3 (en) * 2002-11-14 2014-01-28 Thermo Fisher Scientific Biosciences Inc. SiRNA directed to tp53
US7250289B2 (en) * 2002-11-20 2007-07-31 Affymetrix, Inc. Methods of genetic analysis of mouse
AU2004220525B2 (en) * 2003-03-12 2011-03-31 Vasgene Therapeutics, Inc. Nucleic acid compounds for inhibiting angiogenesis and tumor growth
NZ567952A (en) 2003-03-24 2009-12-24 Sequoia Pharmaceuticals Inc Long acting biologically active conjugates
WO2004092343A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
EP1617864A4 (en) 2003-04-11 2006-06-21 Medimmune Inc Epha2 and non-neoplastic hyperproliferative cell disorders
US7604799B2 (en) 2003-06-06 2009-10-20 Medimmune, Llc EphA4 Antibodies
EP2441474B1 (en) 2003-10-17 2015-08-05 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
CA2546763A1 (en) 2003-11-20 2005-06-09 Medimmune, Inc. Epha2 agonistic monoclonal antibodies and methods of use thereof
CN101072797B (en) 2004-03-12 2012-05-09 瓦斯基因治疗公司 Antibody binding EPHB4, inhibiting angiogenesis and tumor growth
EP2301963A1 (en) 2004-09-23 2011-03-30 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234520A1 (en) * 1998-11-20 2004-11-25 Michel Aguet Uses for Eph receptor antagonists and agonists
US20040247592A1 (en) * 2001-07-03 2004-12-09 Roifman Chaim M. Ephrin and eph receptor mediated immune modulation
US20040110150A1 (en) * 2002-12-10 2004-06-10 Isis Pharmaceuticals Inc. Modulation of Ephrin-B2 expression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1606305A4 *

Also Published As

Publication number Publication date
US7862816B2 (en) 2011-01-04
EP1606305A2 (en) 2005-12-21
JP2011256179A (en) 2011-12-22
US20100093831A1 (en) 2010-04-15
US7585967B2 (en) 2009-09-08
JP4762889B2 (en) 2011-08-31
EP1605961A4 (en) 2009-11-11
EP1606305A4 (en) 2009-06-24
EP1605961A2 (en) 2005-12-21
CA2518898A1 (en) 2004-09-23
WO2004080425A2 (en) 2004-09-23
US20050084873A1 (en) 2005-04-21
AU2004220459A1 (en) 2004-09-23
AU2010238577B2 (en) 2012-05-24
AU2004220525B2 (en) 2011-03-31
AU2010238577A1 (en) 2010-11-18
US20110129482A1 (en) 2011-06-02
WO2004080418A2 (en) 2004-09-23
AU2004220459B2 (en) 2010-08-05
JP2006521111A (en) 2006-09-21
AU2004220525A1 (en) 2004-09-23
US20070031435A1 (en) 2007-02-08
US8063183B2 (en) 2011-11-22
WO2004080425A3 (en) 2005-07-07
CA2518912A1 (en) 2004-09-23
US20050164965A1 (en) 2005-07-28
JP2006519610A (en) 2006-08-31

Similar Documents

Publication Publication Date Title
WO2004080418A3 (en) Nucleic acid compounds for inhibiting angiogenesis and tumor growth
WO2006034455A3 (en) Polipeptide compounds for inhibiting angiogenesis and tumor growth
WO2005062977A3 (en) Prostate cancer specific internalizing human antibodies
WO2006009765A3 (en) Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
WO2003080582A3 (en) Fredericamycin derivatives
WO2005084295A3 (en) Fused heterotricyclic compounds as inhibitors of 17b-hydroxysteroid dehydrogenase 3
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
WO2006015060A3 (en) Isoindoline compounds and methods of their use
WO2007079164A3 (en) Protein kinase inhibitors
WO2006102504A3 (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
AU2003297318A1 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
WO2003084475A3 (en) INHIBITORS OF THE S100-p53 PROTEIN-PROTEIN INTERACTION AND METHOD OF INHIBITING CANCER EMPLOYING THE SAME
WO2005089294A3 (en) Synthesis of indenoisoquinoliniums and methods of use
WO2004033666A3 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
WO2004043379A3 (en) Chemical compounds
WO2004069160A3 (en) Chemical compounds
WO2004058158A3 (en) Treatment of metastatic cancer with the b-subunit of shiga toxin
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006507095

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2518898

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004220525

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004720327

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004220525

Country of ref document: AU

Date of ref document: 20040312

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004220525

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004720327

Country of ref document: EP